March 4, 2015Open Access

Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Although missing data weaken interpretation of the findings, administration of goserelin with chemotherapy appeared to protect against ovarian failure, reducing the risk of early menopause and improving prospects for fertility. (Funded by the National Cancer Institute and others; POEMS/S0230 ClinicalTrials.gov number, NCT00068601.).

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Moore et al. (Wed,) studied this question.

synapsesocial.com/papers/69dd40fcac7bdbc6c71013ab https://doi.org/https://doi.org/10.1056/nejmoa1413204

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo2010 · 45 citations
2RETRACTED: Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study2008 · 329 citations
3Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist Cetrorelix with growth inhibition2009 · 45 citations
4Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer2014 · 747 citations
5Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial2009 · 259 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo